A Phase 4 interventional study of rituximab and Methotrexate in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 4 sites in Korea, Republic of. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-11-04.
Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing rituximab in Arthritis, Rheumatoid — 5 open to participants now, 6 under way, 1 of them phase 3. Rituximab · Arthritis, Rheumatoid.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, this one is the 51st largest by enrollment, is one of 11 that started in 2007, is one of 14 in phase 4, and was the 13th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 63 studies testing rituximab in Arthritis, Rheumatoid are open now, in 4 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 13 · Phase 3 27 · Phase 4 14
First in 2001; this study’s year is marked. 11 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is below the median of 96 across 2,223 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 159 across the 63 interventional studies. Of the 57 that completed or were terminated, 37 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 63 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 109th largest by enrollment of the 141 interventional ones that give a count, is one of 15 that started in 2007, is one of 28 in phase 4, and was the 31st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 63 studies testing rituximab in Arthritis, Rheumatoid, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This single arm study will evaluate the efficacy and safety of MabThera in combination with methotrexate in patients with rheumatoid arthritis who have had an inadequate response to one or more anti-TNF therapies. Patients will receive MabThera 1000mg i.v. on days 1 and 15, and methotrexate (10-25mg/week p.o. or parenteral), together with methylprednisolone 100mg i.v. prior to infusion of MabThera. After week 24, eligible patients may receive re-treatment. The anticipated time on study treatment is 3-12 months, and the target sample size is \<100 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received rituximab 1000 milligrams (mg), intravenously (IV), on Day 1 and Day 15. Participants also received methylprednisolone 100 mg, IV, 30 minutes before the infusion of rituximab. Participants also received methotrexate (MTX) 10 to 25 milligrams per week (mg/week), orally (PO) or parenterally, and folate greater than or equal to (≥) 5 mg/week, PO, folate greater than or equal to (≥) 5 mg/week, PO, either as a single dose or as divided daily doses from Day 1 through Week 24. Participants also received prednisone less than or equal to (≤) 10 milligrams per day (mg/day), PO, OR equivalent corticosteroid, OR non-steroidal anti-inflammatory drugs (NSAIDs), PO, from Day 1 through Week 24. Eligible participants who completed the first 24-week course were entered into a second course.
Drug: rituximab · Drug: Methotrexate · Drug: Corticosteroid or NSAID · Dietary Supplement: Folate
1000 mg i.v. on Days 1 and 15
Also known as: MabThera, Rituxan
10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24
ACR20 response: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; Patient Global Assessment of Disease Activity (PtGA); Physician Global Assessment of Disease Activity (PGA); self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ-DI\]); and either C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR).
Time frame: Week 24
Percentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 24
ACR50 response: ≥50% improvement in tender joint count; ≥50% improvement in swollen joint count; and ≥50% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.
Time frame: Week 24
Percentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 24
ACR70 response: ≥70% improvement in tender joint count; ≥70% improvement in swollen joint count; and ≥70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.
Time frame: Week 24
Disease Activity Score Based on 28-Joint Count (DAS-28)
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (millimeters per hour \[mm/hr\]) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
Time frame: Baseline and Week 24
Percentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.2
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity.
Time frame: Baseline, Week 24
Percentage of Participants With DAS Response by European League Against Rheumatism (EULAR) Category at Week 24
The percentage of participants categorized as good, moderate, or nonresponders according to the EULAR response criteria at Week 24. Participants were categorized as good responders if the intensity of their symptoms was in the "low disease activity (DAS28 less than \[\<\]3.2)" category after treatment, and their symptoms significantly decreased to \>1.2. Participants were categorized as moderate responders if the intensity of their symptoms was in the "moderate or high disease activity (DAS28 \>3.2)" category after treatment, and the symptoms significantly decreased to \>1.2; or if the intensity of their symptoms was in the "low or moderate disease activity (DAS28 \<5.1)" category, and the DAS28 score changed more than 0.6 or 1.2 or less. Participants were categorized as non-responders if they did not fall into the good or moderate categories.
Time frame: Week 24
Swollen Join Count (SJC)
Number of swollen joints was determined by examination of 66 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit as swollen or not swollen.
Time frame: Baseline, Weeks 24 and 48
Tender Joint Count (TJC)
Number of tender joints was determined by examination of 68 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of tender joints was recorded on the joint assessment form at each visit as either tender or not tender.
Time frame: Baseline, Weeks 24 and 48
Patient Global Assessment of Disease Activity (VAS)
The mean score of the symptoms of rheumatoid arthritis (RA) at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100 mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24 and 48
Physician Global Assessment of Disease Activity (VAS)
The mean score of the symptoms of RA at Week 0 and the change from Week 0 (baseline) to Weeks 24 and 48 as assessed by investigators using a 100-mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.
Time frame: Baseline, Weeks 24 and 48
Patient Assessment of Pain (VAS)
The mean score of pain at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100-mm horizontal VAS, where the left endpoint indicated "No pain," and the right endpoint indicated "Unbearable pain." A negative change indicated improvement.
Time frame: Baseline, Weeks 24 and 48
C-reactive Protein (CRP) Level
The mean level of CRP in milligrams per liter (mg/L), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
Erythrocyte Sedimentation Rate (ESR)
The mean level of ESR (in mm/hr), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.
Time frame: Baseline, Weeks 24 and 48
HAQ-DI Score
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Time frame: Baseline, Weeks 24 and 48
Physical Function as Assessed by Short Form 36 (SF-36)
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Screening, Weeks 24 and 48
SF-36 Mental Component Scores
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Time frame: Screening, Weeks 24 and 48
Modified Total Sharp-Genant Score (mTSS)
Posterior-anterior (PA) radiograph of each hand and anterior-posterior (AP) radiograph of each foot were taken separately and assessed according to Genant's method as modified from Sharp's method. The Sharp-Genant score=total of the erosion score and the joint space narrowing (JSN) score of all the hands and feet. Erosion Score: 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. JSN Score:13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total erosion score in hands=100 and in feet=42; maximum scores for JSN in the hands=100 and in feet=48. Maximum modified Sharp score achievable is 290. A lower number change from Baseline indicated a better score. Change in scores was calculated as change=final score minus initial score.
Time frame: Screening and Weeks 24 and 48
Modified Sharp Radiographic Erosion Score (ES)
Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Maximum total erosion score in the hands was 100 and in the feet was 42, for a maximum overall score of 142. Total erosion score was for both hands and feet.
Time frame: Screening, Weeks 24 and 48
Modified Sharp Radiographic Joint Space Narrowing Score (JSN)
JSN Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total scores for JSN in the hands was 100 and in the feet was 48, for a maximum overall score of 148. Total JSN was for both hands and feet.
Time frame: Screening, Weeks 24 and 48
| Milestone | Rituximab, Methotrexate |
|---|---|
| Started | 40 |
| Completed first course | 38 |
| Completed | 37 |
| Not completed | 3 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Did not complete second course | 1 |
ACR20 response: ≥20% improvement in tender joint count; ≥20% improvement in swollen joint count; and ≥20% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; Patient Global Assessment of Disease Activity (PtGA); Physician Global Assessment of Disease Activity (PGA); self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ-DI\]); and either C-Reactive Protein (CRP) or erythrocyte sedimentation rate (ESR).
| percentage of participants | Rituximab, Methotrexate |
|---|---|
| Percentage of Participants With An American College of Rheumatology 20 Percent (%) Improvement Criteria (ACR20) Response at Week 24 | 47.5 (31.5 to 63.9) |
ACR50 response: ≥50% improvement in tender joint count; ≥50% improvement in swollen joint count; and ≥50% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.
| percentage of participants | Rituximab, Methotrexate |
|---|---|
| Percentage of Participants With An American College of Rheumatology 50% Improvement Criteria (ACR50) Response at Week 24 | 7.5 (1.6 to 20.4) |
ACR70 response: ≥70% improvement in tender joint count; ≥70% improvement in swollen joint count; and ≥70% improvement in at least 3 of 5 remaining ACR core measures: Patient Assessment of Pain; PtGA; PGA; self-assessed disability (HAQ-DI); and either CRP or ESR.
| percentage of participants | Rituximab, Methotrexate |
|---|---|
| Percentage of Participants With An American College of Rheumatology 70% Improvement Criteria (ACR70) Response at Week 24 | 5.0 (0.6 to 16.9) |
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (millimeters per hour \[mm/hr\]) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity. DAS28 ≤3.2 equals (=) low disease activity, DAS28 greater than (\>)3.2 to 5.1 = moderate to high disease activity.
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Week 0 | 6.76 ± 1.02 |
| Week 24 | 5.31 ± 1.16 |
| Change at Week 24 | -1.45 ± 0.94 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity.
| percentage of participants | Rituximab, Methotrexate |
|---|---|
| Percentage of Participants With Change in DAS-28 From BL to Week 24 of ≥1.2 | 60.0 |
The percentage of participants categorized as good, moderate, or nonresponders according to the EULAR response criteria at Week 24. Participants were categorized as good responders if the intensity of their symptoms was in the "low disease activity (DAS28 less than \[\<\]3.2)" category after treatment, and their symptoms significantly decreased to \>1.2. Participants were categorized as moderate responders if the intensity of their symptoms was in the "moderate or high disease activity (DAS28 \>3.2)" category after treatment, and the symptoms significantly decreased to \>1.2; or if the intensity of their symptoms was in the "low or moderate disease activity (DAS28 \<5.1)" category, and the DAS28 score changed more than 0.6 or 1.2 or less. Participants were categorized as non-responders if they did not fall into the good or moderate categories.
| percentage of participants | Rituximab, Methotrexate |
|---|---|
| Good responders | 5.0 |
| Moderate responders | 65.0 |
| Nonresponders | 30.0 |
Number of swollen joints was determined by examination of 66 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit as swollen or not swollen.
| swollen joints | Rituximab, Methotrexate |
|---|---|
| Week 0 | 16.3 ± 8.4 |
| Change at Week 24 | -8.9 ± 6.2 |
| Change at Week 48 | -11.6 ± 7.2 |
Number of tender joints was determined by examination of 68 joints (as assessed through pressing and palpating during the physical examination) and identifying when swelling was present. The number of tender joints was recorded on the joint assessment form at each visit as either tender or not tender.
| tender joints | Rituximab, Methotrexate |
|---|---|
| Week 0 | 21.9 ± 14.0 |
| Change at Week 24 | -9.0 ± 9.3 |
| Change at Week 48 | -13.9 ± 11.1 |
The mean score of the symptoms of rheumatoid arthritis (RA) at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100 mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.
| mm | Rituximab, Methotrexate |
|---|---|
| Week 0 | 72.6 ± 21.6 |
| Change at Week 24 | -20.5 ± 25.8 |
| Change at Week 48 | -31.8 ± 26.9 |
The mean score of the symptoms of RA at Week 0 and the change from Week 0 (baseline) to Weeks 24 and 48 as assessed by investigators using a 100-mm horizontal VAS, where the left endpoint indicated "No disease activity" (no symptom, or no symptom of RA), and the right endpoint indicated "Maximum disease activity" (maximum RA activity). A negative change from Baseline indicated improvement.
| mm | Rituximab, Methotrexate |
|---|---|
| Week 0 | 72.8 ± 13.4 |
| Change at Week 24 | -30.4 ± 24.1 |
| Change at Week 48 | -42.1 ± 23.0 |
The mean score of pain at Week 0 (baseline) and the change from Week 0 to Weeks 24 and 48 as assessed by participants using a 100-mm horizontal VAS, where the left endpoint indicated "No pain," and the right endpoint indicated "Unbearable pain." A negative change indicated improvement.
| mm | Rituximab, Methotrexate |
|---|---|
| Week 0 | 69.3 ± 20.7 |
| Change at Week 24 | -16.8 ± 26.1 |
| Change at Week 48 | -28.2 ± 26.8 |
The mean level of CRP in milligrams per liter (mg/L), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.
| mg/L | Rituximab, Methotrexate |
|---|---|
| Week 0 | 3.80 ± 4.32 |
| Change at Week 24 | -1.54 ± 3.85 |
| Change at Week 48 | -2.23 ± 3.01 |
The mean level of ESR (in mm/hr), an acute phase reactant, at Week 0 and the change from Week 0 to Weeks 24 and 48.
| mm/hr | Rituximab, Methotrexate |
|---|---|
| Week 0 | 77.2 ± 28.6 |
| Change at Week 24 | -23.4 ± 27.1 |
| Change at Week 48 | -36.1 ± 26.0 |
HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Week 0 | 1.66 ± 0.70 |
| Change at Week 24 | -0.34 ± 0.58 |
| Change at Week 48 | -0.53 ± 0.64 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Screening, Physical functioning (n=39) | 27.7 ± 17.2 |
| Screening, Role-physical (n=39) | 26.6 ± 21.5 |
| Screening, Bodily pain (n=39) | 29.2 ± 17.5 |
| Screening, General health (n=39) | 31.7 ± 16.2 |
| Week 24, Physical functioning (n=39) | 35.8 ± 22.5 |
| Week 24, Role-physical (n=39) | 41.5 ± 23.1 |
| Week 24, Bodily pain (n=39) | 44.7 ± 19.7 |
| Week 24, General health (n=39) | 38.1 ± 17.1 |
| Week 48, Physical functioning (n=39) | 43.4 ± 26.7 |
| Week 48, Role-physical (n=38) | 49.3 ± 29.0 |
| Week 48, Bodily pain (n=38) | 50.9 ± 22.7 |
| Week 48, General health (n=38) | 44.9 ± 22.7 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Screening, Vitality (n=38) | 30.3 ± 18.6 |
| Screening, Social functioning (n=39) | 41.7 ± 26.8 |
| Screening, Role-emotional (n=39) | 36.8 ± 25.3 |
| Screening, Mental health (n=38) | 52.9 ± 19.5 |
| Week 24, Vitality (n=39) | 35.7 ± 21.2 |
| Week 24, Social functioning (n=39) | 55.5 ± 25.6 |
| Week 24, Role-emotional (n=39) | 53.9 ± 27.6 |
| Week 24, Mental health (n=39) | 56.0 ± 21.4 |
| Week 48, Vitality (n=38) | 44.2 ± 26.6 |
| Week 48, Social functioning (n=38) | 63.2 ± 26.0 |
| Week 48, Role-emotional (n=38) | 55.5 ± 31.9 |
| Week 48, Mental health (n=38) | 60.7 ± 23.9 |
Posterior-anterior (PA) radiograph of each hand and anterior-posterior (AP) radiograph of each foot were taken separately and assessed according to Genant's method as modified from Sharp's method. The Sharp-Genant score=total of the erosion score and the joint space narrowing (JSN) score of all the hands and feet. Erosion Score: 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. JSN Score:13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total erosion score in hands=100 and in feet=42; maximum scores for JSN in the hands=100 and in feet=48. Maximum modified Sharp score achievable is 290. A lower number change from Baseline indicated a better score. Change in scores was calculated as change=final score minus initial score.
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Screening | 79.5 ± 48.5 |
| Change at Week 24 | 0.26 ± 0.55 |
| Change at Week 48 | 0.64 ± 1.16 |
Erosion Score: A total of 14 locations in each hand and wrist and 6 joints in the foot were evaluated for erosion using an 8-point scale where 0=Normal to 3.5=very severe erosion. Maximum total erosion score in the hands was 100 and in the feet was 42, for a maximum overall score of 142. Total erosion score was for both hands and feet.
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Screening | 25.2 ± 25.1 |
| Change at Week 24 | 0.18 ± 0.42 |
| Change at Week 48 | 0.49 ± 0.89 |
JSN Score: A total of 13 locations in each hand and wrist and 6 joints in the foot were evaluated for joint narrowing score using a 9-point scale where 0=Normal to 4.0=definite ankylosis (stiffness or fixation of a joint). Maximum total scores for JSN in the hands was 100 and in the feet was 48, for a maximum overall score of 148. Total JSN was for both hands and feet.
| scores on a scale | Rituximab, Methotrexate |
|---|---|
| Screening | 54.3 ± 27.6 |
| Change at Week 24 | 0.08 ± 0.24 |
| Change at Week 48 | 0.15 ± 0.51 |
Collected over Adverse events (AEs) were reported from Screening up through Week 48 or Withdrawal Visit.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Rituximab, Methotrexate | — | 6/40 (15%) | 38/40 (95%) |
| Event | Rituximab, Methotrexate |
|---|---|
| AppendicitisGastrointestinal disorders | 2/40 |
| Arthritis bacterialInfections and infestations | 1/40 |
| InfectionInfections and infestations | 1/40 |
| Scrub typhusInfections and infestations | 1/40 |
| ConcussionInjury, poisoning and procedural complications | 1/40 |
| Knee arthroplastySurgical and medical procedures | 1/40 |
| Event | Rituximab, Methotrexate |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 12/40 |
| RashSkin and subcutaneous tissue disorders | 6/40 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/40 |
| Feeling hotGeneral disorders | 4/40 |
| Pharyngolaryngeal painRespiratory, thoracic and mediastinal disorders | 4/40 |
| OnychomycosisInfections and infestations | 3/40 |
| MyalgiaMusculoskeletal and connective tissue disorders | 3/40 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/40 |
| AlopeciaSkin and subcutaneous tissue disorders | 3/40 |
| PruritusSkin and subcutaneous tissue disorders | 3/40 |
Intent to treat (ITT) population included all enrolled participants who received the investigational treatment.
| Age, Continuous(years) | Rituximab, Methotrexate |
|---|---|
| Mean | 49.9 ± 11.4 |
| Sex: Female, Male(Participants) | Rituximab, Methotrexate |
|---|---|
| Female | 34 |
| Male | 6 |
The record gives a start of Jun 2007, a primary completion of Jul 2009 and a completion of Jul 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2014, 5 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Rituximab · Methotrexate